Canaan Partners: ThirtyFiveBio Closes Bridge Financing

ThirtyFiveBio, an Oxford, UK-based biotechnology company developing small molecule inhibitors for the treatment of gastrointestinal (GI) disease, closed a Bridge financing of an undisclosed amount